Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States

BACKGROUND: Lumacaftor/ivacaftor was approved by the Food and Drug Administration (FDA) as a combination treatment for Cystic Fibrosis (CF) patients who are homozygous for the F508del mutation. The objective of this study was to assess the cost-effectiveness of lumacaftor/ivacaftor combination for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Dolly, Xing, Shan, Hung, Yu-Ting, Caskey, Rachel N., Dowell, Maria L., Touchette, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162947/
https://www.ncbi.nlm.nih.gov/pubmed/30268148
http://dx.doi.org/10.1186/s13023-018-0914-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162947/
https://www.ncbi.nlm.nih.gov/pubmed/30268148
http://dx.doi.org/10.1186/s13023-018-0914-3

Ejemplares similares